

Fermenta Biotech Limited (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



File no. 49

May 6, 2021

Corporate Relations

BSE Limited,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400 001.

Dear Sir,

Sub.: Outcome of Board Meeting - Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Ref: Scrip Code: 506414.

This is to inform you that the Board of Directors of the Company ('Board') at its meeting held on May 6, 2021 has, *inter alia*, approved the following:

- (i) appointment of Mr. Krishna Datla (DIN: 00003247) as a Whole-time Director of the Company (Key Managerial Personnel), designated as Executive Vice-Chairman, for a period of 3 years commencing from May 9, 2021 to May 8, 2024, subject to members' approval at their ensuing general meeting.
- (ii) appointment Mr. Prashant Nagre (DIN: 09165447) as an additional director on the Board of Directors of the Company w.e.f. May 6, 2021; and
- (iii) appointment of Mr. Prashant Nagre as (DIN: 09165447) as the Managing Director of the Company (Key Managerial Personnel) for a period of 3 years commencing from May 9, 2021 to May 8, 2024, subject to members' approval at their ensuing general meeting.

Factory : Village Takoli, P.O. Nagwain,
Dist. Mandi - 175 121, Himachal Pradesh, India.
Tel. : +91-1905-287246 / 48 / 49
Fax: +91-1905-287250
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,
Taluka - Vagara, Dist. Bharuch - 392 130,
Gujarat, India.
Tel. : +91-2641-291440 / 444
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com

Fermenta Biotech Limited (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



Requisite details of directors in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and affirmation pursuant to BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018 are provided in Annexure 1.

A copy of the Press Release for the same is attached for your intimation and records.

The Board meeting commenced at 11.30 a.m. am and concluded at 01.15 pm.

Thanking you,

Yours faithfully,

for **Fermenta Biotech Limited**

(Formerly known as DIL Limited)

Srikant N Sharma

Company Secretary

CS Membership No: F3617

A-1501, Thane One, DIL Complex, Majiwade, Thane (W) 400610

Encl: (1) Annexure 1

(2) A copy of the Press Release

Factory : Village Takoli, P.O. Nagwain,
Dist. Mandi - 175 121, Himachal Pradesh, India.
Tel. : +91-1905-287246 / 48 / 49
Fax: +91-1905-287250
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,
Taluka - Vagara, Dist: Bharuch - 392 130,
Gujarat, India.
Tel. : +91-2641-291440 / 444
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com



Annexure 1
Details of Directors

Sr.	Particulars	Mr. Krishna Datla	Mr. Prashant Nagre
1	Reason for change viz. appointment, resignation, removal, death or otherwise	The Board of Directors at its meeting held on May 06, 2021, appointed Mr. Krishna Datla as a Whole-time Director of the Company, designated as the Executive Vice-Chairman, subject to members' approval.	The Board of Directors at its meeting held on May 06, 2021, appointed Mr. Prashant Nagre as an Additional Director of the Company. He is also appointed by the Board as the Managing Director of the Company, subject to members' approval.
2	Date of appointment/cessation (as applicable) & term of appointment	Mr. Krishna Datla has been appointed a Whole-time Director of the Company, designated as the Executive Vice-Chairman, with effect from 9 th May 2021, for a term of 3 (three) years, subject to members' approval.	Mr. Prashant Nagre is appointed as an Additional Director w.e.f. 6 th May 2021 and shall hold the office of Additional Directorship up to the date of the next annual general meeting of the Company. Mr. Prashant Nagre has been appointed as the Managing Director with effect from 9 th May, 2021, for a term of 3 (three) years, subject to members' approval.
3	Brief profile (in case of appointment)	Mr. Krishna Datla is a promoter and the Managing Director of the Company from 9 th May, 2005 till 8 th May, 2021. He has played a key role in the Company's decision-making	Mr. Nagre is currently the Chief Executive Officer of the company. Nearly three decades in the pharmaceuticals industry, he has in-depth experience across spheres encompassing the API business, production, Research and

Fermenta Biotech Limited (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



		<p>process and also oversees new businesses of the Company.</p> <p>Credited with the integration of businesses across the various group companies, Mr. Krishna Datla has infused a strong sense of global vision thereby opening the opportunities across international markets.</p> <p>He has over 20 years of experience.</p> <p>Mr. Datla is a Commerce Graduate from Mumbai University.</p>	<p>Development and regulatory compliances.</p> <p>He has led corporate strategy, business operations and demand-driven innovation for FBL's three business verticals viz., Vitamin D and other APIs, Integrated Biotechnology and Environmental Solutions.</p> <p>He holds a master's degree in management sciences, and also a Post Graduate Diploma in International Trade (IIFT, New Delhi), besides a Degree in Pharmacy.</p>
4	Disclosure of relationships between directors (in case of appointment of a director).	He is relative of Ms. Anupama Datla Desai, Executive Director and Ms. Rajeshwari Datla, Non-Executive Director, as per Section 2(77) of the Companies Act, 2013	Nil
5	Affirmation pursuant to BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018 that director debarred from holding the office of director	It is affirmed that Mr. Krishna Datla is not debarred from holding the office(s) of director by virtue of any SEBI order or any other such authority.	It is affirmed that Mr. Prashant Nagre is not debarred from holding the office(s) of director by virtue of any SEBI order or any other such authority.

Prashant Nagre elevated to the position of Managing Director of Fermenta Biotech Limited

Strategic decision to fuel next phase of growth for the company

Mumbai, 6th May 2021:

Mr Krishna Datla, Promoter and Managing Director of Fermenta Biotech Limited (FBL) today announced the appointment of Chief Executive Officer, Prashant Nagre, as the new Managing Director with effect from 9th May 2021. Mr Datla will continue as a Board member and the Executive Vice Chairman.

The last few years have witnessed implementation of significant strategic decisions being spearheaded by the management and Board of FBL, such as acquisition of equity shares from its earlier PE investor followed by the merger with its parent company for enhancing operational synergies. The current announcement is another such step taken by the promoters towards inculcating greater professionalization of the company to fuel its growth ambitions.

Prashant Nagre joined FBL in 2010 as the Chief Operating Officer and in two years, was elevated to the position of Chief Executive Officer. Since then, he has led corporate strategy, business operations and demand-driven innovation for FBL's three business verticals viz., Vitamin D and other APIs, Integrated Biotechnology and Environmental Solutions. Under the leadership of Mr Datla, during Prashant's tenure, FBL has expanded from a solely domestic-focused business to a global vitamin player, with more than 70% of revenues now arising from exports. Prashant will also be responsible for steering the company's efforts to foray into the nutrition segment by developing a future-ready organization with a value-added portfolio.

Mr Krishna Datla commented, "Prashant has led various transformational milestones for accelerating the organization's progress, and we have immense faith in his leadership. As the company is evolving into a global entity, we think, Prashant is aptly suited to achieve our strategic vision. Prashant's track record at FBL coupled with his vast professional experience will be instrumental in driving the next phase of growth. We welcome Prashant on the Board and look forward to taking our success to newer heights."

Commenting on his new role, Prashant Nagre said, "It has been a privilege to serve the organization for more than a decade. It is with great humility that I accept my new role, and I am honoured to lead the team at such an exciting time for the company. Moving ahead, I am confident that FBL will enter a new chapter in its growth story and will continue to strive towards creating a better future for all our stakeholders."



About Fermenta Biotech Ltd. (FBL):

Fermenta Biotech Limited (FBL) is one of the leading manufacturers of Vitamin D3 globally. It caters to over 300 customers across 50 countries with a worldwide distribution network for a variety of applications such as pharmaceuticals, dietary and nutritional supplements, food, animal nutrition and rodenticides. FBL's manufacturing facilities in Kullu and Dahej are certificated by global accreditations and its world class R&D centre is located at Thane. Apart from Vitamin D3, FBL also possesses expertise in integrated biotechnology solutions such as enzymes for antibiotic synthesis and other niche APIs.

For more information about the Company and its businesses, please visit our website www.fermentabiotech.com

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

For Fermenta Biotech Limited

Name : Mr. Sumesh Gandhi
Designation : Chief Financial Officer
Email ID. : sumesh.gandhi@fermentabiotech.com